Business Context and Reporting Period
Company: Icecure Medical Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: December 2025 (Report No. 4)
Date of Filing: December 17, 2025
This filing serves to incorporate by reference a press release issued on December 17, 2025, regarding the Company's expected sales performance and recent regulatory milestones.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses on qualitative expectations rather than historical financial data.
Material Changes and Developments
- Regulatory Milestone: The Company received FDA clearance for its ProSense Cryoablation system for the treatment of low-risk breast cancer.
- Sales Outlook: Management expects to report record fourth-quarter sales in North America, driven by the aforementioned FDA clearance.
Guidance, Outlook, and Management Commentary
Management commentary is limited to the press release incorporated by reference. The primary outlook indicates a positive trajectory for North American sales in the fourth quarter of 2025 due to the new indication for ProSense Cryoablation. No specific financial guidance, risk factors, or contingencies are detailed within the text of this Form 6-K.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for specific sales projections or quantitative details not included in this summary.
- Confirm the scope and limitations of the FDA clearance for ProSense Cryoablation regarding low-risk breast cancer.
- Review subsequent filings for actual fourth-quarter financial results to validate the "record sales" expectation.
- Check the Company's Registration Statements on Form F-3 and Form S-8 where this press release is incorporated by reference.